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Abstract (162 words): 
Dysregulation of cell division resulting in aberrant cell proliferation is a key hallmark of 
cancer, making it a rational and important target for innovative anti-cancer drug 
development. Three selective CDK4/6 inhibitors are FDA and EMEA approved for hormone 
receptor positive/HER2 negative advanced breast cancer. A major emerging appreciation is 
that these inhibitors are not only cytostatic, but also play critical roles in the interaction 
between tumour cells and the host immune response. However, to trigger an effective 
immune response, lymphocytes must also proliferate.  This review aims to assimilate our 
emerging understanding on the role of CDK4/6 inhibitors in cell cycle control, as well as their 
biological effect on T cells and other key immune cells, and the confluence of preclinical 
evidence of augmentation of anti-cancer immunity by these drugs. We aim to provide a 
framework for understanding the role of the cell cycle in anti-cancer immunity, discussing 
ongoing clinical trials evaluating this concept and challenges for developing rational 
combinations with immune-therapy.  
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Introduction: 1 
The mammalian cell cycle is a highly organised and regulated process that ensures 2 
duplication of genetic material and cell division (1). Key features of this process are 3 
cascades of growth-regulatory signals and signalling proteins that monitor genetic integrity. 4 
Proliferation depends on progression from the quiescent state (G0) though four distinct 5 
phases; G1, the first gap phase, S phase, DNA synthesis, G2, the second gap phase and M, 6 
mitosis  – which is controlled at checkpoints by cyclins and their associated cyclin-dependent 7 
kinases (CDKs) (2). Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of 8 
the cell cycle and required for entry into, and progression through G1.  9 
 10 
Unsurprisingly, this intricate process is disrupted in most cancers (3), either as a result of 11 
mutations in upstream signalling pathways, or by defects in genes encoding cell cycle 12 
proteins (reviewed in (4)). Specific inhibitors of CDK4/6 have been touted as paradigm-13 
shifting with recent FDA and EMEA approval for three orally available inhibitors – Palbociclib 14 
(PD-0332991; Ibrance; Pfizer, Inc.), Ribociclib (LEE011; Kisqali; Novartis) and 15 
Abemaciclib (LY2835219; Verzenio; Lilly) (5-7). In contrast to traditional chemotherapeutic 16 
agents, CDK4/6 inhibitors arrest progression through G1, promoting transient quiescence or 17 
inducing senescence and have shown significant clinical benefit in combination with 18 
aromatase inhibitors, the selective oestrogen receptor degrader, fulvestrant, and tamoxifen 19 
(8).  20 
 21 
Translational outputs from these ongoing trials have unexpectedly revealed effects of 22 
CDK4/6 inhibitors in several critical roles underpinning the interactions of cancer cells with 23 
the host immune system (9-11). The cell cycle cascade couples two processes that are 24 
required for the generation of an effective adaptive immune response; clonal expansion and 25 
differentiation, and consequently, CDK inhibitors have the potential to participate in the 26 
decision between tolerance, anergy and the promotion of anti-tumour immunity.   27 
 28 
In this review, we discuss the biological functions of the CDK4-CDK6-Retinoblastoma 29 
(CDK4/6-Rb) axis - both when pathologically hijacked in cancer and also physiologically in 30 
immune cells, with a view to providing a framework for understanding the role of the cell 31 
cycle in anti-cancer immunity. We discuss emerging preclinical and clinical data showing 32 
effects of CDK4/6 inhibition on promoting various aspects of anti-tumour immunity including 33 
enhancing antigen presentation, depleting immunosuppressive regulatory T cells, and 34 
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ultimately shifting the balance towards the generation of an efficient anti-tumour immune 35 
response. We also ponder the challenges faced by ongoing clinical trials attempting to 36 
therapeutically target these together with immunotherapy.  37 
 38 
The biology of the Cyclin D-CDK4/6-Rb axis  39 
Numerous detailed reviews of this pathway are available (e.g. (4, 12)). This review will 40 
therefore focus on the major principles of this axis. Quiescent cells in G0 can be triggered to 41 
re-enter the cell cycle through stimulation by a variety of mitogenic factors that activate 42 
intricate intracellular signalling networks that are ‘sensed’ by the holoenzyme complex of 43 
Cyclin D and CDK4 and/or CDK6 (4) (Figure 1). Evolutionarily highly conserved, there are 44 
three mammalian Cyclin Ds that have overlapping functions in a cell-lineage specific 45 
manner. These allosterically bind to and regulate cyclin-dependent kinases 4 and 6 - two 46 
highly homologous serine/threonine kinases that have unique functions that are cell-type 47 
specific as well as being tightly developmentally and temporally regulated (13, 14). CDK6 is 48 
expressed at high levels in hematopoietic cells (14, 15) and Cdk6 deficiency is characterized 49 
by subtle defects in the hematopoietic system, such as defects in thymocyte development 50 
(13, 16). CDK6 is also a more robust kinase (as compared to CDK4) with distinct affinities for 51 
specific modulatory client proteins, and together these two Cyclin D-dependent CDKs allow 52 
for the creation of a network of finely tuned interactions to regulate cell cycle progression 53 
(17). Activation of the Cyclin D-CDK4/6 complex promotes progression from the G1 phase 54 
into S phase by phosphorylating several cellular targets, of which the Retinoblastoma protein 55 
(Rb) is key (18). Rb phosphorylation attenuates its inhibition of transcription by the E2F 56 
family of transcription factors, leading to the commitment of the cell to DNA replication and 57 
progression through the cell cycle (19).   58 
  59 
The role of the Cyclin D-CDK4/6-Rb pathway in cancer  60 
In cancer, multiple components of the CDK4/6-Rb axis are commonly dysregulated (20). The 61 
Cyclin D1 gene (CCND1) represents the second most frequently amplified locus among all 62 
human cancer types (21), with the highest prevalence in well-differentiated and 63 
dedifferentiated liposarcoma (22),  glioblastomas (23),  breast cancer  (24-26), non-small cell 64 
lung cancer (NSCLC), endometrial cancers and pancreatic cancers  (24). Copy number 65 
variation or overexpression in at least one component of the cyclin D-CDK4/6 pathway is 66 
also common and seen in up to 75% of melanoma (27) and gliomas (28). Loss of the 67 
negative regulators of the pathway either by genomic deletions, loss-of-function point 68 
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mutations or promoter methylation are also frequent, with p16INK4A most commonly lost in 69 
breast cancers (29) and head and neck cancers (30). However, other than in mantle cell 70 
lymphoma, which is defined by a translocation involving CCND1 resulting in cyclin D1 71 
overexpression (31), mutations in genes encoding for the pathway are less common than 72 
copy number changes (32).  73 
 74 
Transcription of Cyclin D and its assembly with CDK4/6 is highly dependent on mitogenic 75 
signaling and is therefore an important mechanism of Cyclin D-CDK4/6 upregulation in 76 
cancer (32). Oestrogen receptor (ER) signaling upregulates cyclin D1 levels as well as other 77 
signaling pathways, which largely culminate in the upregulation of CDK4/6 activity (6, 33, 78 
34). Other upstream oncogenic signal transduction pathways including the PI3K-AKT-79 
mTOR, wnt/β-catenin, mitogen-activated protein kinase (MAPK), and nuclear factor kappa-80 
light-chain-enhancer of activated B cells (NF-κB) pathways, also significantly lead to the 81 
induction of cell cycle proteins, and D-type Cyclins in particular (6, 35). 82 
 83 
Single agent, CDK4/6 inhibitors in vitro, are fundamentally cytostatic, causing 84 
downregulation of E2F target genes, loss of proliferation markers and cell cycle arrest in G1 85 
(36).  It can therefore be hypothesised that cancer cells addicted to mitogenic signaling 86 
pathways and have functional Rb are strongly dependent on Cyclin D-CDK4/6 and thereby 87 
more vulnerable to CDK4/6 inhibition; this has been elegantly demonstrated in vitro (37). 88 
However, only modest clinical benefit has been reported in the various unselected early 89 
phase trials of single agent CDK 4/6 monotherapy including in NSCLC, glioblastoma (GBM), 90 
melanoma, colorectal and ovarian cancers as well as in mantle cell lymphoma and advanced 91 
liposarcoma. One exception to this is abemaciclib (which at clinically efficacious doses also 92 
inhibits CDK9) and has shown potentially useful single agent activity in breast cancer leading 93 
to licensing as monotherapy in previously treated advanced breast cancer patients (38). 94 
Furthermore, the randomized JUNIPER study (NCT02152631) will evaluate its monotherapy 95 
efficacy in non-small cell lung cancer. 96 
 97 
Given the striking dependence of activated Cyclin D-CDK4/6 complex on mitogenic signals, 98 
there has been substantial work developing synergistic combinations of signal transduction 99 
inhibitors together with CDK4/6 inhibitors. The most advanced combinations are those in 100 
with endocrine therapies in oestrogen-positive breast cancer, which led to the first FDA 101 
approvals. The pivotal Phase II PALOMA-1 (NCT 00721409) study randomized post-102 
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menopausal women with advanced ER+/HER2- breast cancer to either Letrozole, an 103 
aromatase inhibitor that prevents oestrogen-induction of Cyclin D, in combination with 104 
Palboclicib, or Letrozole alone (39). The significant improvement of progression-free survival 105 
in the combination arm (20.2 months vs 10.2 months for Letrozole alone; hazard ratio 106 
HR=0.48 P<0.001) led to early provisional FDA approval of Palboclicib. Subsequent larger 107 
phase III trials have not only confirmed these results (7, 40, 41) but extended the proof-of-108 
principle of synergy in combining other CDK4/6 inhibitors with the selective oestrogen 109 
receptor degrader, fulvestrant (42, 43) or the anti-oestrogen, tamoxifen (41, 44).   110 
 111 
The concept, that combinatorial therapy with signal transduction inhibitors will amplify the 112 
effectiveness of a CDK4/6 inhibitor, is now being extended to other mitogenic pathways and 113 
other tumour types. For example, pre-clinical evidence to suggest CDK4/6 inhibitors 114 
enhance the effect of RAS–RAF–MEK pathway inhibition in RAS-driven NSCLC (45) and 115 
RAS/RAF resistant malignant melanoma (46) has led to early phase trials of combination 116 
therapy in KRAS mutant NSCLC (NCT02022982) and NRAS and BRAF mutant melanoma 117 
(47, 48). Hyperactivation of the PI3K pathway has also been shown to stabilise the Cyclin D 118 
protein and the Cyclin D-CDK4/6 complex (49), and CDK4/6 inhibitors have been shown 119 
preclinically to sensitise PIK3CA mutant breast cancer to PI3K inhibitors (50). Triplet 120 
combinations of CDK4/6 inhibitors together with hormone therapies and PI3K inhibitors are 121 
also ongoing in breast cancer (NCT03006172)  (51-53). 122 
 123 
One really interesting observation that may be pivotal is that in addition to blocking cell 124 
proliferation, CDK4/6 inhibitors can induce senescence – an irreversible distinct cellular state 125 
characterized by the by absence of proliferation markers, expression of tumour suppressor 126 
genes, senescence-associated beta-galactosidase activity and the presence of senescence-127 
associated heterochromatin foci in multiple Rb-proficient cell lines (54, 55). The decision 128 
whether to transition from quiescence into senescence is the subject of much ongoing work  129 
and the outcome appears to cell-type specific with downregulation of MDM2, redistribution of 130 
the chromatin-remodelling enzyme ATRX, repressions of oncogenes as well as upregulation 131 
of proteasomal homeostasis necessary for the shift to senescence (56-58).  Senescent cells 132 
secrete a collection of inflammatory cytokines, chemokines and proteinases, collectively 133 
referred to as the senescence associated secretory phenotype (SASP) which recruits and 134 
activates distinct cells from the innate and adaptive immune system, such as macrophages 135 
and NK cells as well as T cells (59, 60). The SASP is one of the most profound features of 136 
senescence with the triggering of immune cell recruitment into the tumour (61, 62), although 137 
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on the other hand there are concerns that the inflammatory environment chronically 138 
stimulated by SASP could be pro-tumourigenic (59).  139 
This raises several obvious questions about the clinical effect of these inhibitors on host 140 
immune cells, and whether this would hinder, or could be leveraged for combination 141 
therapies. In the following sections, we review the role of Cyclin D-CDK4/6 in immune cell 142 
expansion and differentiation, together with the emerging learnings from the translations 143 
studies of CDK4/6 inhibitors.  144 
The role of the Cyclin D- CDK4/6-Rb pathway in immune cell biology 145 
Mouse models provided the first clues to the physiological roles of Cdk4 and Cdk6 in vivo, 146 
particularly with respect to the immune cell types that critically depend upon the Cyclin D-147 
CDK4/6 pathway during development. Double mutant mice lacking both Cdk4 and Cdk6 148 
(Cdk4/6-/- mice) display late embryonic lethality accompanied by a defect in fetal 149 
haematopoiesis very similar to the phenotype observed in the triple D1/2/3-cyclins−/− mice, 150 
including multilineage haematopoietic abnormalities (13, 63).  151 
 152 
Myeloid lineage     153 
Myeloid cell development in preclinical models is entirely reliant on Cyclin D2 and Cyclin D3-154 
driven CDK6 (13, 64) and all myeloid progenitor cells populations were also severely 155 
reduced in Cdk4/6-/- double mutant mice (13).   156 
Not unsurprisingly, neutropenia has been the dose-limiting toxicity of both palbociclib and 157 
ribociclib, necessitating intermittent dosing schedules (65, 66). Abemaciclib, being a more-158 
potent inhibitor of CDK4 (as well as inhibiting CDK9 at clinically efficacious doses) seems 159 
distinct and causes much lower rates of neutropenia (Table 1) and can be dosed on a 160 
continuous schedule (67). An ongoing study of palbociclib is investigating whether a 161 
continuous dosing schedule (at 100mg/day) is as effective and tolerable as the approved 162 
intermittent dosing schedule (NCT 02630693). Clinical data on the changes in other myeloid 163 
cell sub-populations is however scarce at this time, chiefly as multi-parameter data analysis 164 
of circulating immune cells or immune cells within the tumour microenvironment was not 165 
collected in the initial trials.  166 
 167 
Lymphoid lineage 168 
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Following antigen exposure, quiescent lymphocytes require intense, prolonged and repeated 169 
proliferation to establish a rapid immune response and generate immunological memory. 170 
Upon stimulation, T cells exit G0 via an NF-κB dependent pathway (68). Cyclin D is 171 
expressed in cells during G1, with significant upregulation of Cyclins D2,D3 and CDK6 172 
during early and late G1 (69, 70) (Figure 2). Deletion of specific Cyclins and CDKs in mice 173 
have identified CDK6 and Cyclin D3 to be the key players in hematopoietic stem cells 174 
regulation, their proliferation and subsequent commitment to the T-cell lineage  (13, 16, 71-175 
73).  Loss of CDK6 leads to delayed G1 progression in lymphocytes, but critically, once a 176 
cell is committed to proliferation, other Cyclins-CDKs, particularly Cyclin E and CDK2 appear 177 
to compensate. As such, despite CDK6 mutant mice having lower numbers of thymocytes 178 
early on in development, they have normal/higher than normal levels of CD4+/CD8+ cells 179 
later in development (64). This is very consistent with the modest reductions in total 180 
lymphocyte numbers seen clinically with the unique differential potency of inhibition of 181 
abemaciclib likely to be responsible for the lack of appreciable leukopenia reported clinically 182 
for abemaciclib (Table 1) (67).  183 
 184 
Commitment to specific cell fates and differentiation with transcriptional activation of specific 185 
gene expression programmes are predominantly directed by CDK2 (74), and as such in vitro 186 
differentiation of naïve CD4+ and CD8+ T cells are not affected by CDK4/6 inhibitors (10). 187 
Specific T cell sub-populations however, may be much more selectively suppressed by 188 
CDK4/6 inhibition as suggested by flow cytometry analysis of circulating immune cells in pre-189 
clinical models. In tumour-free mice, both abemaciclib and palbociclib significantly reduced 190 
FOXP3+  regulatory T cells (10) without affecting other cell sub-types, and this may relate to 191 
the higher levels of both Cyclin D as well as CDK4/6 (75, 76) or Rb1 present in these cells 192 
(77).  Abemaciclib may also have additional epigenetic effects by selectively inhibiting the 193 
enzyme DNMT1 in regulatory T cells, resulting in overexpression of the negative regulator 194 
p21 (10). The effects of CDK4/6 inhibition on tumour-infiltrating lymphocytes may be more 195 
complex with both palboclicib and trilaciclib causing increased infiltration of T cells into lung 196 
tumours in an immunocompetent genetically engineered mouse model (GEMM). In this 197 
model, absolute numbers of CD4+ and CD8+ cells were unchanged, but proliferation of 198 
tumour infiltrating FOXP3+ regulatory cells as well as immunosuppressive myeloid cells 199 
were significantly reduced resulting in an increased percentage of effector cells within the 200 
tumour microenvironment (9). 201 
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In summary, the data thus far reveals that while therapeutic targeting of CDK4/6 can 202 
theoretically slow T cell proliferation, in vivo it has a preferential effect of promoting cell 203 
differentiation while specifically depleting regulatory T cells (9, 10). (Figure 2) 204 
 205 
Effects of CDK4/6 inhibition on the tumour microenvironment and the tumour-host 206 
immune reaction 207 
Enhancing immune cell infiltration into tumour 208 
Cell cycle arrest and the induction of senescence leads to the activation of the SASP in a 209 
subset of cancer cells which can induce the recruitment of innate immune cells including 210 
macrophages, neutrophils and natural killer cells into the tumour microenvironment where 211 
they are provoked into coordinately attacking tumours through both phagocytosis and direct 212 
cytotoxic killing (62, 67).  The challenge remains in understanding how tumour cells are 213 
directed toward either reversible quiescence or a more stable senescence, as preliminary 214 
work in a small subset of abemaclicib-sensitive breast cancer cell lines suggest that genes 215 
encoding for the canonical SASP cytokines were not shown to be upregulated in the cell 216 
lines tested (11).   217 
 218 
Enhancing antigen presentation 219 
The initial studies suggesting links between CDK4/6 inhibition and the immune system came 220 
from a Rb proficient transgenic mouse model of breast cancer (10).  Treatment with 221 
Abemaciclib caused not only cell stasis but also a significant decrease in tumour volume and 222 
reduced cell proliferation (10). Gene expression analysis has shown that in addition to 223 
downregulating genes related to cell cycle, mitotic and E2F targets, abemaciclib also 224 
significantly upregulates genes responsible for antigen processing and presentation 225 
including major histocompatibility complex (MHC) class I molecules (10). This was confirmed 226 
in vitro as well as in patient-derived xenografts.  Strikingly, tumour cells treated with CDK4/6 227 
inhibitors show a marked reduction of DNMT1, which decreases DNA methylation of genes 228 
that regulate immune function, as well as endogenous retroviral genes (ERVs). Expression 229 
of double-stranded RNA, triggers ‘viral mimicry’ stimulating the production of an interferon 230 
response (10) (Figure 3).  231 
Further support of this model comes from data from the Cancer Genome Atlas (TCGA) 232 
showing that breast cancers harbouring CCND1 amplification (therefore enhanced CDK4/6 233 
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activity) display significantly lower expression of major histocompatibility complex (MHC) 234 
class I molecules HLA-A, HLA-B and HLA-C than non-amplified tumours (10).  235 
 236 
Effects on cytokine milieu in tumour microenvironment  237 
Additionally, Deng et al used a small molecule screen designed to identify targets that 238 
enhanced T cell activity in the setting of PD-1 engagement and found that CDK4/6 inhibitors 239 
potently upregulated IL-2 (9). Using short interfering RNAs, they confirmed that CDK6, not 240 
CDK4 was responsible for the enhanced IL-2 secretion supporting a predominant role for 241 
CDK6 in immune cell function.  Careful dissection of the mechanistic basis of this effect 242 
found that CDK6 was an upstream regulator of Nuclear Factor of Activated T cells (NFAT) 243 
proteins which are critical in regulation of T cell activation and function. CDK4/6 inhibition 244 
resulted in increased nuclear levels of NFAT and increased transcriptional activity ultimately 245 
resulting in a change in cytokine milieu within the tumour microenvironment and increased 246 
effector T cell activity (9, 11). Levels of IL-6, IL-10 and IL-23, three cytokines produced by 247 
immunosuppressive myeloid cells, were significantly reduced, while an increase of the Th1 248 
chemokines CXCL9 and CXCL10 which govern the trafficking of effector cells to tumour 249 
sites was seen (9, 78).  250 
 251 
Effects on PD-L1 and other co-inhibitor molecule expression 252 
PD-L1 protein abundance fluctuates during cell cycle progression in multiple human cancer 253 
cell lines, peaking in M and early G1, with a sharp reduction in latter stages of the cell cycle. 254 
This is tightly regulated by Cyclin D-CDK4 mediated phosphorylation of the speckle-type 255 
POZ protein, a core component of the Cullin3-SPOP E3 ligase responsible for the 256 
proteasomal degradation of PD-L1 (79). Inhibition of CDK4/6 in this single paper increases 257 
PD-L1 expression, but only in SPOP-proficient cancer cells. The story is far from complete 258 
though, as effects of CDK4/6 inhibition on the expression of other co-inhibitory molecules, 259 
particularly on immune cells is likely to be complex. For example in the GEMM mouse model 260 
used by Deng et al, levels of the co-inhibitory molecular PD-1 and CTLA-4 were reduced in 261 
both CD4+ and CD8+ T cells after CDK4/6 inhibition (9). 262 
 263 
Taken together, these studies illustrate the complex connection between immunity and cell-264 
cycle regulation and constitute an exciting new area of research, which is likely to lead to 265 
significant anti-cancer therapeutic opportunities and pharmacodynamic and transalational 266 
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outputs from the ongoing clinical trials are eagerly awaited. Combining CDK4/6 inhibitors 267 
together with immune checkpoint inhibitors enhance tumour regression in a number of 268 
immunocompetent preclinical mice models (9, 79).  These effects seem to be at least in part 269 
to be tumour-intrinsic, as most potent upregulation of the antigen processing machinery at a 270 
gene expression level occurred in CDK4/6 sensitive cell lines (10). Additionally, there are 271 
hints that as cancers evolve, and undergo immune-editing thus becoming more immune-272 
refractory, they may be increasingly dependent on Cyclin D-CDK4/6. Oh et al studied a 273 
highly immune-refractory cancer and found that synaptonemal complex protein 3 (SCP3) is 274 
overexpressed in immune-edited cancer cells and upregulates the pluripotency 275 
transcriptional factor NANOG by hyperactivation of the Cyclin D-CDK4/6 axis. In this model, 276 
the combination of Palbociclib together with adoptive cytotoxic cell transfer showed 277 
considerable therapeutic efficacy, suggesting a niche role for CDK4/6 inhibitors in 278 
immunotherapy combinations in the resistant/refractory setting (80).  279 
 280 
 281 
Challenges for the future  282 
The ongoing clinical trials testing combinations of CDK4/6 inhibitors with immune checkpoint 283 
inhibitors are listed in Table 2, but a few specific challenges in combining these are worth 284 
exploring.   Understanding the temporal kinetics of pharmacodynamics effects of CDK4/6 285 
inhibitors on the tumour microenvironment and the immune system would be key to 286 
optimising sequencing of any combinations. Schaer et al looked at the differences in anti-287 
tumour responses when anti-PD-L1 therapy was given either concurrently, sequentially (after 288 
completion of CDK4/6 inhibitor) or in a phased (initiated after 1 week of CDK4/6 inhibitor) 289 
manner with abemaciclib (11). Surprisingly, concurrent administration of abemaciclib with 290 
immune checkpoint inhibitors showed no significant difference in the anti-tumour response 291 
compared to monotherapy. Sequential treatment was additive, but the phased regime was 292 
significantly synergistic, with complete responses seen in 2/10 mice (11) highlighting the 293 
importance of understanding the biology to direct scheduling of combinations. Furthermore, 294 
they analysed the effect of transient vs continuous exposure to abemaciclib on primary T 295 
cells during TCR-mediated expansion and found that the greatest effect in upregulating 296 
genes indicated of T cell activation was seen with the continuous exposure. This may be 297 
pertinent when other CDK4/6 inhibitors that are given intermittently are considered for 298 
combinations. Moving forward, it will be absolutely imperative that proof-of-mechanism 299 
pharmacodynamics studies utilising paired tumour biopsies as well as in-depth analyses of 300 
host immune responses be incorporated into these trials to maximise patient benefit.  301 
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Biomarker driven patient selection is also likely to direct these combinations to the patients 302 
who are most likely to derive benefit; for example if loss of MHC I expression or markers of T 303 
cell exhaustion are seen, combinations of phased in pre-treatment with CDK4/6 inhibitors 304 
given with immunotherapy may be therapeutically beneficial. Paraphrasing Shakespeare, 305 
much more remains to be learned about how a cell decides whether to cycle or to fight, and 306 
future work will reveal if the promise of combining CDK4/6 inhibitors with immunotherapy will 307 
be realised and validated.  308 
  309 
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Table 1. Myelosuppression seen in the initial early phase trials of single agent CDK4/6 inhibitors.  310 
*Indicates dose-limiting toxicity.  311 
 312 
         
         
   Palboclicib Riboclicib Abemaclicib  
      
IC50 CDK4  9-11 nmol/L 10 nmol/L 2 nmol/L 
 CDK6  15 nmol/L 39 nmol/L 5 nmol/L 
 
Dosing    125mg daily  
3 weeks on 1 week off 
600mg daily 
3 weeks on 1 week off 
200mg daily  
continuously     
  
Effects on immune cells  All grades G3/4 All 
grades 
G3/4 All 
grades 
G3/4 
 neutropenia  95% 54%* 46% 29%* 23% 10% 
 leukopenia  68% 23% 48% 21% 25% 10% 
                  
Reference    NCT00141297 NCT01237236 NCT01394016 
 313 
 314 
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Table 2. Ongoing clinical trials combining CDK4/6 inhibitors with immune check-point inhibitors 
Trial name/ID Phase Patient population Combination agents 
Primary 
objective 
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer/ 
NCT03294694 
I 
HR-positive HER2-negative Breast Cancer 
Epithelial Ovarian Cancer 
Ribociclib 
PDR001 - PD-1 Inhibitor 
Fulvestrant 
MTD/RP2D 
PACT/  
NCT02791334 
I  
 
Solid Tumour 
Microsatellite Instability-High (MSI-H) Solid 
Tumors 
Cutaneous Melanoma 
Pancreatic Cancer 
Breast Cancer (HR+HER2-) 
 
LY3300054 - PD-1 Inhibitor 
Ramucirumab 
Abemaciclib 
Merestinib 
 
 
DLT 
A Study of Abemaciclib (LY2835219) in Participants With 
Non-Small Cell Lung Cancer or Breast Cancer/ 
NCT02779751 
I 
Non Small Cell Lung Cancer 
HR-positive HER2-negative Breast Cancer 
 
Abemaciclib 
Pembrolizumab 
AEs 
PAVEMENT – A Phase Ib Study of Palbociclib and 
Avelumab in Metastatic AR+ triple negative breast cancer 
 (NCT pending) 
Ib 
Androgen-receptor positive triple negative 
Breast Cancer  
Palbociclib  
Avelumab 
R2PD 
AEs, adverse events; ER+, estrogen receptor-positive; DLT, dose-limiting toxicity; HER2, human epidermal growth factor receptor 2; MTD, maximum tolerated dose; RP2D, 
recommended Phase II dose; 
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Figure legends 
Figure 1 Regulation and functions of cyclin D–CDK4/6 kinases. The Cyclin D-CDK4/6 holoenzyme 
complex (green boxed) acts as an environmental sensor responding dynamically to mitogenic signals 
(e.g., oestrogen, Ras-Raf-MEK, EGFR and PI3K signaling pathways), cytokines, and other cues. Upon 
stimulation, D-type cyclins accumulate in early G1 phase through both transcriptional and 
posttranscriptional mechanisms. The activated cyclin D–CDK4/6 complexes initiates the 
phosphorylation of pRb releasing E2F transcription factors thereby driving the expression of genes 
required for cellular commitment to enter S-phase, and ultimately mitotic cell division. Growth-
inhibitory signals antagonize G1–S progression by upregulating CDK inhibitors of the INK4 family 
(p16INK4A, p15INKB, p18INK4C and p19INK4D ).  
 
Amplification of the CCND1 gene encoding for Cyclin D or its overexpression, loss of stoichiometric 
inhibitors of cyclin D–CDK4/6 (members of the INK4A family), or the loss of Rb in tumours aberrantly 
activate the Cyclin D-CDK4/6 complex thereby driving dysregulated cell cycle progression.  
 
Depending on the cell type, and other mitogenic transforming signals, Rb-positive cells undergo 
either quiescence or senescence when treated with CDK4/6 inhibitors. In contrast, cells without 
function Rb are refractory to arrest by chemical inhibitors of CDK4/6.  
   
Figure 2 Cyclin D-CDK4/6 in T cell activation, expansion and differentiation 
The figure shows relative levels of CDK4/6 and D type Cyclins at the various stages of the cell cycle as 
naïve T cells respond to antigen stimulation, enter the cell cycle, undergo clonal expansion followed 
by maturation and subsequent differentiation. Lilac boxes highlight cells with high levels of CDK4/6 
and D type Cyclins, while light green indicates cells with low levels.  
 
Stimulation of the TCR together with costimulatory signals (eg CD28) leads to the induction of a 
number of cell cycle activators, including cyclin-dependent kinases (CDKs) 4/6 and D-type cyclins 
which set off a signalling cascade permitting progression through the G1 phase of the cell 
cycle.  Subsequent progression through S phase is accompanied by downregulation of both CDK4/6 
and D type cyclins in an oscillating manner as cells undergo repeated cycles of cell division. As cells 
differentiate, Cyclin D remain low in the majority of T cells, with the exception of regulatory T cells 
which retain high expression of both Cyclin D as well as CDK4/6 (75, 76). As such, while therapeutic 
targeting of CDK4/6 can theoretically slow T cell proliferation, in vivo it has a preferential effect of 
promoting cell differentiation while specifically depleting regulatory T cells (9, 10).  
 
Figure 3 To cycle or fight 
Tumours with hyperactivation of the Cyclin D-CDK4/6 axis aberrantly progress through the cell cycle 
and effectively hide from the host immune system through multiple mechanisms including down 
regulation of MHC Class I molecules.  
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Treatment with CDK4/6 inhibitors both arrests cell cycle but also promotes a ‘fight’ mode, promoting 
anti-tumour immunity by stimulating antigen presentation through 1) the upregulation of MHC Class 
I expression within tumours and 2) the increase in pro-inflammatory cytokine secretion (eg IFN) 
either via inducing the senescence associated secretory phenotype (SASP) or other mechanism 
resulting in activation of dendritic cells and macrophages. CDK4/6 inhibitors also selectively deplete 
immunosuppressive regulatory T cells and change the cytokine milleu within the tumour 
microenvironment, thereby increasing effector T cell infiltration into the tumour. (9, 10, 11) 
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